BR9808254A - Compostos, uso e processo para a preparação dos mesmos, composição farmacêutica, e, processo para tratamento da depressão, ansiedade, doença de parkinson, obesidade, desordens cognitivas, doenças repentinas, desordens neurológicas e de neuroproteção para proteger contra condições tais como derrame cerebral em seres humanos. - Google Patents

Compostos, uso e processo para a preparação dos mesmos, composição farmacêutica, e, processo para tratamento da depressão, ansiedade, doença de parkinson, obesidade, desordens cognitivas, doenças repentinas, desordens neurológicas e de neuroproteção para proteger contra condições tais como derrame cerebral em seres humanos.

Info

Publication number
BR9808254A
BR9808254A BR9808254-0A BR9808254A BR9808254A BR 9808254 A BR9808254 A BR 9808254A BR 9808254 A BR9808254 A BR 9808254A BR 9808254 A BR9808254 A BR 9808254A
Authority
BR
Brazil
Prior art keywords
carbon atoms
compounds
optionally substituted
disorders
anxiety
Prior art date
Application number
BR9808254-0A
Other languages
English (en)
Inventor
Sharon Crawford Cheetham
Frank Kerrigan
Colin Gerhart Pryce Jones
Original Assignee
Knoll Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Ag filed Critical Knoll Ag
Publication of BR9808254A publication Critical patent/BR9808254A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/42Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"COMPOSTOS, USO E PROCESSO PARA A PREPARAçãO DOS MESMOS, COMPOSIçãO FARMACêUTICA, E, PROCESSO PARA TRATAMENTO DA DEPRESSãO, ANSIEDADE, DOENçA DE PARKINSON, OBESIDADE, DESORDENS COGNITIVAS, DOENçAS REPENTINAS, DESORDENS NEUROLóGICAS E DE NEUROPROTEçãO PARA PROTEGER CONTRA CONDIçõES TAIS COMO DERRAME CEREBRAL EM SERES HUMANOS". São descritos compostos de fórmula (I): incluindo seus sais farmaceuticamente aceitáveis na forma de enanciómeros individuais, racematos, ou outras misturas de enanciómeros, em que Ar é fenila, naftila ou benzo[b]tiofenila, cada um dos quais pode ser opcionalmente substituído; R~ 1~ e R~ 2~, que podem ser os mesmos ou diferentes, independentemente são a) H, b) um grupo alquila contendo de 1 a 6 átomos de carbono, c) um grupo alquenila contendo de 3 a 6 átomos de carbono, d) um grupo cicloalquila contendo de 3 a 7 átomos de carbono, e) um grupo cicloalquilmetila em que o anel contém de 3 a 7 átomos de carbono, f) um grupo arila ou heteroarila opcionalmente substituído, g) um grupo arilalquila ou heteroarilalquila cada um opcionalmente substituído; ou R~ 1~ e R~ 2~ formam uma cadeia de alquileno opcionalmente substituída por um ou mais grupos de alquila cada um contendo de 1 a 3 átomos de carbono, tal que, juntamente com os átomos a que eles são ligados, eles formam um anel de 5 ou 6 membros; R~ 3~ é a) H, b) um grupo arila ou heteroarila cada um opcionalmente substituído, c) um grupo arilmetila opcionalmente substituído; ou d) um grupo alcoxialquila contendo de 3 a 6 átomos de carbono; e R~ 4~ e R~ 5~, que podem ser os mesmos ou diferentes, independentemente são um grupo alquila contendo de 1 a 3 átomos de carbono, ou R~ 4~ e R~ 5~ juntamente com o átomo a qual eles são ligados formam um anel ciclo alquila contendo de 3 a 6 átomos de carbono; processos para preparar tais compostos; composições contendo tais compostos e seu uso no tratamento de depressão, ansiedade, doença de Parkinson, obesidade, desordens cognitivas, doenças repentinas, desordens neurológicas e como agentes neuroprotetores.
BR9808254-0A 1997-03-15 1998-03-09 Compostos, uso e processo para a preparação dos mesmos, composição farmacêutica, e, processo para tratamento da depressão, ansiedade, doença de parkinson, obesidade, desordens cognitivas, doenças repentinas, desordens neurológicas e de neuroproteção para proteger contra condições tais como derrame cerebral em seres humanos. BR9808254A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9705428.2A GB9705428D0 (en) 1997-03-15 1997-03-15 Therapeutic agents
PCT/EP1998/001358 WO1998041528A1 (en) 1997-03-15 1998-03-09 Substituted 4-arylmethylene-2-imino-2,3-dihydrothiazoles and derivatives and their pharmaceutical use

Publications (1)

Publication Number Publication Date
BR9808254A true BR9808254A (pt) 2000-05-16

Family

ID=10809320

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9808254-0A BR9808254A (pt) 1997-03-15 1998-03-09 Compostos, uso e processo para a preparação dos mesmos, composição farmacêutica, e, processo para tratamento da depressão, ansiedade, doença de parkinson, obesidade, desordens cognitivas, doenças repentinas, desordens neurológicas e de neuroproteção para proteger contra condições tais como derrame cerebral em seres humanos.

Country Status (22)

Country Link
US (1) US6187802B1 (pt)
EP (1) EP0970090B1 (pt)
JP (1) JP2001515501A (pt)
KR (1) KR20000076190A (pt)
CN (1) CN1255136A (pt)
AT (1) ATE218573T1 (pt)
AU (1) AU6728898A (pt)
BG (1) BG103754A (pt)
BR (1) BR9808254A (pt)
CA (1) CA2283438A1 (pt)
DE (1) DE69805781D1 (pt)
GB (1) GB9705428D0 (pt)
HU (1) HUP0001508A3 (pt)
ID (1) ID22636A (pt)
IL (1) IL131515A0 (pt)
NO (1) NO994452D0 (pt)
NZ (1) NZ337378A (pt)
PL (1) PL335696A1 (pt)
SK (1) SK122099A3 (pt)
TR (1) TR199902291T2 (pt)
WO (1) WO1998041528A1 (pt)
ZA (1) ZA982134B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19856965A1 (de) * 1998-12-10 2000-06-15 Bayer Ag Substituierte 2-Imino-thiazoline
WO2000056308A1 (en) 1999-03-19 2000-09-28 Knoll Pharmaceutical Company Prevention of cardiovascular disease
AU3760600A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of orthostatic hypotension
US6803387B1 (en) 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
JP2002539250A (ja) 1999-03-19 2002-11-19 クノール・ゲー・エム・ベー・ハー 肺高血圧症の治療
US6441046B1 (en) 1999-03-19 2002-08-27 Abbott Gmbh & Co. Kg Control of metabolism
AU3899100A (en) 1999-03-19 2000-10-09 Knoll Pharmaceutical Company Treatment of hyperactivity disorders
US6376554B1 (en) 1999-03-19 2002-04-23 Knoll Pharmaceutical Company Method of treating sexual dysfunction
US6376551B1 (en) 1999-03-19 2002-04-23 Knoll Pharmaceutical Company Treatment of chronic fatigue syndrome
GB9911881D0 (en) * 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
GB9911863D0 (en) * 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
FR2796643B1 (fr) * 1999-07-22 2005-04-29 Sod Conseils Rech Applic Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique
GB0005789D0 (en) 2000-03-11 2000-05-03 Knoll Ag Therapeutic agents
US6699866B2 (en) 2001-04-17 2004-03-02 Sepracor Inc. Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
PT1453505E (pt) * 2001-12-11 2010-12-16 Univ Virginia Utilização de pramipexol para tratamento da esclerose lateral amiotrófica
US6743797B2 (en) * 2002-02-22 2004-06-01 Chantest, Inc. Methods for treating cardiac arrhythmia
US20050054010A1 (en) * 2003-07-15 2005-03-10 Brown Arthur M. High throughput assay systems and methods for identifying agents that alter surface expression of integral membrane proteins
US7211407B2 (en) * 2003-07-15 2007-05-01 Chan Test, Inc. High throughput assay systems and methods for identifying agents that alter surface expression of integral membrane proteins
US20050208595A1 (en) * 2004-03-19 2005-09-22 Brown Arthur M High throughput assay systems and methods for identifying agents that alter expression of cellular proteins
EP1917014B1 (en) * 2005-08-15 2009-10-07 University Of Virginia Patent Foundation Neurorestoration with r(+) pramipexole
NZ569630A (en) * 2006-01-06 2011-09-30 Sepracor Inc Cycloalkylamines as monoamine reuptake inhibitors
KR100752757B1 (ko) * 2006-04-05 2007-08-29 한국과학기술연구원 2-페닐이미노-1,3-티아졸린을 포함하는 미백 조성물
US20070259930A1 (en) * 2006-04-10 2007-11-08 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
WO2007137071A2 (en) 2006-05-16 2007-11-29 Knopp Neurosciences, Inc. Compositions of r(+) and s(-) pramipexole and methods of using the same
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
CN101715443A (zh) 2007-03-14 2010-05-26 诺普神经科学股份有限公司 手性纯化的取代的苯并噻唑二胺的合成
US20110190356A1 (en) * 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
KR101049935B1 (ko) * 2008-12-03 2011-07-15 한국과학기술연구원 신규한 티아졸린계 화합물 및 이를 포함하는 t-형 칼슘 채널 저해제
JP2012530723A (ja) * 2009-06-19 2012-12-06 ノップ ニューロサイエンシーズ、インク. 筋萎縮性側索硬化症を治療するための組成物及び方法
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US10828284B2 (en) 2013-07-12 2020-11-10 Knopp Biosciences Llc Compositions and methods for treating conditions related to elevated levels of eosinophils and/or basophils
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
CA2921378A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
AU2014306597B2 (en) 2013-08-13 2018-05-17 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4347248A (en) 1981-03-23 1982-08-31 American Cyanamid Company 2,3-Disubstituted-thiazolo[3,2-a]pyrimidines
US5232921A (en) 1987-03-12 1993-08-03 Sanofi Thiazole derivatives active on the cholinergic system, process for obtention and pharmaceutical compositions
FR2612187B1 (fr) * 1987-03-12 1989-07-21 Sanofi Sa Derives du thiazole actifs sur le systeme cholinergique, leur procede de preparation et compositions pharmaceutiques en contenant
US5463069A (en) 1992-12-04 1995-10-31 Sumitomo Chemical Company, Limited Process of producing 2-iminothiazoline derivatives and process of producing their intermediates
US5521145A (en) 1994-04-04 1996-05-28 Sumitomo Chemical Company, Ltd. Iminothiazoline derivatives and herbicides containing them as active ingredients
GB9513467D0 (en) * 1995-07-01 1995-09-06 Knoll Ag Therapeutic agents

Also Published As

Publication number Publication date
AU6728898A (en) 1998-10-12
JP2001515501A (ja) 2001-09-18
GB9705428D0 (en) 1997-04-30
WO1998041528A1 (en) 1998-09-24
DE69805781D1 (de) 2002-07-11
IL131515A0 (en) 2001-01-28
ZA982134B (en) 1999-09-13
KR20000076190A (ko) 2000-12-26
NO994452L (no) 1999-09-14
ATE218573T1 (de) 2002-06-15
CN1255136A (zh) 2000-05-31
HUP0001508A3 (en) 2003-01-28
CA2283438A1 (en) 1998-09-24
BG103754A (bg) 2000-06-30
EP0970090B1 (en) 2002-06-05
SK122099A3 (en) 2000-05-16
US6187802B1 (en) 2001-02-13
ID22636A (id) 1999-12-02
TR199902291T2 (xx) 1999-12-21
EP0970090A1 (en) 2000-01-12
PL335696A1 (en) 2000-05-08
NZ337378A (en) 2001-01-26
HUP0001508A2 (hu) 2001-01-29
NO994452D0 (no) 1999-09-14

Similar Documents

Publication Publication Date Title
BR9808254A (pt) Compostos, uso e processo para a preparação dos mesmos, composição farmacêutica, e, processo para tratamento da depressão, ansiedade, doença de parkinson, obesidade, desordens cognitivas, doenças repentinas, desordens neurológicas e de neuroproteção para proteger contra condições tais como derrame cerebral em seres humanos.
BR0008128A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, método para produzir um efeito antiangiogênico e/ ou de redução da permeabilidade vascular em um animal de sangue quente com a necessidade de tal tratamento, e, processo para a preparação de um composto
FI954130A0 (fi) Heterosykliset yhdisteet ja niiden valmistus ja käyttö
SE7910501L (sv) Lekemedel for behandling av det centrala nervsystemet
BR0010716A (pt) Compostos de fenila substituìdos com atividade imunossupressora e composições farmacêuticas
UA19171A (uk) Спосіб одержаhhя фіhілалкіламіhів або їх фармакологічhо прийhятhих солей
AR029150A1 (es) Un derivado de piperidina, su empleo, un procedimiento para prepararlo y una composicin farmaceutica que lo comprende.
AR026974A1 (es) N-[5-[[[5-alquil-2-oxazolil]metil]tio]-2-tiazolil]-carboxamidas, utiles como inhibidores de cinasas dependientes de ciclina, y las composicionesfarmaceuticas que los contienen
KR900016203A (ko) 신규 화합물들
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
KR910004559A (ko) 중추 신경계에 작용하는 무스카린성 약제인 4-(n-치환 아미노)-2-부티닐-1-우레아 및 티오우레아와 그의 유도체
PT99864A (pt) Processo para a preparacao de novas composicoes farmaceuticas contendo antagonistas de receptor de quisqualato
ATE147626T1 (de) Verwendung von pirenzepine, telenzepine oder o- methoxy -sila-hexocyclium zur herstellung eines medikaments zur behandlung und regulierung der augenentwicklung
BR0315756A (pt) Derivado de quinazolina ou um seu sal farmaceuticamente aceitável, processo para a preparação do mesmo, composição farmacêutica, uso do dito derivado ou de um seu sal farmaceuticamente aceitável, e, método para produzir um efeito anti-invasivo pela detenção e/ou pelo tratamento de doença de tumor sólido em um animal de sangue quente necessitando de tal tratamento
MX9707596A (es) Benzamidas, el uso de las mismas, composiciones que las contienen, para el tratamiento del transtorno neurodegenerativo, y procedimiento para la preparacion del mismo.
ZA894048B (en) New condensed diazepinones,processes for preparing them and pharmaceutical compositions containing these compounds
UA66751C2 (en) Benzamides as medicament for treatment of neurodegenerative state, a method for the preparation thereof (variants), pharnaceutical composition for treatment of neurodegenerative states and a method for treatment
BRPI0410613A (pt) preparação de quinoxalinas substituìdas a partir da dianlina com 2,3-diidróxi-1,4-dioxano
GB8608893D0 (en) D-nor-7-ergoline derivatives
OA09379A (fr) Polyméthylène-imines disubstituées, leur procédé de préparation et les compositions pharmaceutiques les contenant.
DE69830840D1 (de) Heterozyklische verbindungen, ihre herstellung und ihre anwendung
RU2221786C2 (ru) Производные тетрагидроизохинолиналканола, способы лечения и фармацевтические композиции на их основе
KR930019640A (ko) 테트라히드로피리미딘 유도체
TH20919A (th) สารประกอบชนิดเฮเทอโรไซคลิคและการเตรียมและการใช้สารประกอบเหล่านี้
KR890003678A (ko) 부정맥 치료제

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007.